CRVS Corvus Pharmaceuticals, Inc. Stock Quote

CRVS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	12.76%	Shs Outstand	29.66M	Perf Week	3.19%
Market Cap	111.45M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	124.25%	Shs Float	23.45M	Perf Month	-1.02%
Income	-6.00M	PEG	-	EPS next Q	-0.33	Inst Own	47.70%	Short Float	5.71%	Perf Quarter	-28.68%
Sales	-	P/S	-	EPS this Y	87.20%	Inst Trans	7.53%	Short Ratio	1.34	Perf Half Y	-30.88%
Book/sh	2.43	P/B	1.20	EPS next Y	17.50%	ROA	-63.60%	Target Price	-	Perf Year	-13.13%
Cash/sh	1.16	P/C	2.52	EPS next 5Y	-	ROE	-78.80%	52W Range	2.51 - 6.88	Perf YTD	-18.26%
Dividend	-	P/FCF	-	EPS past 5Y	33.30%	ROI	-	52W High	-57.70%	Beta	1.65
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	-	Gross Margin	-	52W Low	15.94%	ATR	0.16
Employees	42	Current Ratio	3.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.79	Volatility	7.03% 5.92%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	345.40%	Profit Margin	-	Rel Volume	0.13	Prev Close	2.94
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 29 AMC	Payout	-	Avg Volume	1.00M	Price	2.91
Recom	2.30	SMA20	4.08%	SMA50	-2.80%	SMA200	-22.19%	Volume	133,674	Change	-1.02%

Feb-10-21

Downgrade

Mizuho

Buy → Neutral

$7 → $4

Sep-12-19

Initiated

Mizuho

Buy

May-29-19

Initiated

ROTH Capital

Buy

Aug-24-17

Upgrade

Credit Suisse

Underperform → Neutral

May-01-17

Downgrade

Credit Suisse

Neutral → Underperform

Apr-18-16

Initiated

Guggenheim

Buy

Apr-18-16

Initiated

Credit Suisse

Outperform

May-05-21 09:00AM	Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program GlobeNewswire
Apr-29-21 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results GlobeNewswire
Apr-20-21 02:51AM	Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Mar-25-21 08:30AM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire +9.09%
Mar-05-21 08:30AM	Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences GlobeNewswire
Feb-18-21 11:38PM	Co-Founder Richard Miller Just Bought 8.5% More Shares In Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Simply Wall St.
Feb-17-21 04:10PM	Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock GlobeNewswire
Feb-12-21 09:00AM	Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.17%
Feb-11-21 04:01PM	Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire -5.06%
Feb-04-21 09:57AM	Corvus Initiates CPI-006 Pivotal Trial In COVID-19 Patients; Results Expected by 2021 End Benzinga
07:30AM	Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19 GlobeNewswire
Jan-30-21 02:53AM	What Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry? Simply Wall St.
Dec-07-20 03:28PM	Is CRVS A Good Stock To Buy Now? Insider Monkey
Dec-06-20 10:00AM	Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire
Nov-30-20 08:00AM	Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire
Nov-11-20 04:05PM	Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting GlobeNewswire
Nov-09-20 08:05AM	Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-02-20 08:00AM	Corvus Pharmaceuticals COVID-19 Abstract Selected for Hot Topic Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-01-20 09:08AM	We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully Simply Wall St.
Oct-29-20 04:00PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results GlobeNewswire +5.00%
08:30AM	Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Oct-07-20 10:39AM	Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates Zacks
Oct-05-20 09:57AM	Corvus Shares Surge After Positive Data From Early COVID Treatment Study TheStreet.com +19.41%
09:48AM	Looking Into Corvus Pharmaceuticals's Return On Capital Employed Benzinga
08:05AM	Shares of Corvus jump on additional data from small Phase 1 trial for COVID-19 treatment MarketWatch
07:24AM	Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China GlobeNewswire
07:22AM	New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19 GlobeNewswire
Sep-17-20 03:01AM	New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020 GlobeNewswire
Sep-11-20 08:30AM	Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors GlobeNewswire
Sep-10-20 08:30AM	Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19 GlobeNewswire +12.86%
Sep-08-20 06:02PM	Corvus Announces Participation in Upcoming Investor Conferences GlobeNewswire +7.40%
Aug-04-20 04:05PM	Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Aug-03-20 11:33AM	How Much Of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Do Insiders Own? Simply Wall St.
Jul-30-20 04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-23-20 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020 GlobeNewswire
Jul-20-20 03:30PM	3 Strong Buy Healthcare Stocks Under $5 That Could Double (Or More) TipRanks +5.62%
Jul-09-20 08:43AM	Corvus Pharmaceuticals (CRVS) Catches Eye: Stock Jumps 8.4% Zacks -6.52%
Jul-08-20 10:22AM	Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More Zacks +8.38%
09:58AM	Corvus Starts Immunotherapy Study on Coronavirus, Stock Rises Zacks
Jul-07-20 09:53AM	Corvus Shoots Up 115% On Start Of Novel Immunotherapy Study In Covid-19 Patients SmarterAnalyst +80.84%
09:32AM	Corvus stock jumps on launch of early-stage trial for coronavirus treatment MarketWatch
08:51AM	Corvus Shares Jump as Study of Novel Virus Therapy Begins TheStreet.com
07:00AM	Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19 GlobeNewswire
Jul-03-20 06:12PM	Should You Buy Corvus Pharmaceuticals, Inc. (CRVS)? Insider Monkey
Jun-24-20 08:40AM	Edited Transcript of CRVS earnings conference call or presentation 30-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
May-29-20 08:00AM	Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signatures Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant GlobeNewswire -5.74%
May-27-20 08:00AM	Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference GlobeNewswire +9.46%
May-20-20 12:00PM	What Makes Corvus (CRVS) a New Buy Stock Zacks
May-13-20 05:23PM	Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program GlobeNewswire
May-04-20 07:26AM	Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth? Simply Wall St. +14.88%
Apr-30-20 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-22-20 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020 GlobeNewswire
Mar-10-20 05:14PM	Edited Transcript of CRVS earnings conference call or presentation 5-Mar-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-05-20 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire -6.87%
Feb-28-20 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2019 Financial Results on March 5, 2020 GlobeNewswire
Feb-19-20 04:05PM	Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium GlobeNewswire
Feb-13-20 08:00AM	Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncologys Genitourinary Cancers Symposium GlobeNewswire
Feb-01-20 02:00PM	Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum GlobeNewswire
Dec-20-19 10:56AM	Hedge Funds Arent Crazy About Corvus Pharmaceuticals, Inc. (CRVS) Anymore Insider Monkey
Dec-17-19 06:28AM	Read This Before Selling Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Simply Wall St. +10.63%
Dec-07-19 09:00AM	Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-08-19 07:00AM	Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -9.21%
Nov-07-19 08:30AM	Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-05-19 08:30AM	Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference GlobeNewswire
Nov-04-19 08:30AM	Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019 GlobeNewswire +12.43%
Nov-02-19 01:01AM	Edited Transcript of CRVS earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-29-19 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-18-19 11:01AM	Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth Simply Wall St.
Oct-17-19 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019 GlobeNewswire +5.71%
Oct-03-19 08:30AM	Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-03-19 01:28PM	How Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Can Impact Your Portfolio Volatility Simply Wall St.
Aug-10-19 11:17AM	Edited Transcript of CRVS earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 04:05PM	Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference GlobeNewswire
Aug-01-19 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-24-19 04:15PM	Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019 GlobeNewswire -6.52%
Jul-03-19 11:14AM	Need To Know: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insiders Have Been Buying Shares Simply Wall St. +25.50%
Jun-02-19 10:45AM	Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting GlobeNewswire
May-28-19 08:30AM	Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-25-19 01:28PM	Edited Transcript of CRVS earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-16-19 08:30AM	Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire -5.86%
May-09-19 05:05PM	Corvus: 1Q Earnings Snapshot Associated Press
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-01-19 04:10PM	Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019 GlobeNewswire
Apr-26-19 03:07PM	Introducing Corvus Pharmaceuticals (NASDAQ:CRVS), The Stock That Slid 65% In The Last Three Years Simply Wall St.
Mar-07-19 04:10PM	Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-05-19 04:15PM	Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-06-19 08:30AM	Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference GlobeNewswire +5.70%
Jan-30-19 08:30AM	Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference GlobeNewswire
Jan-28-19 04:05PM	Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer GlobeNewswire
Jan-22-19 12:05PM	Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares This Year? Simply Wall St. -8.98%
Jan-10-19 08:30AM	Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas GlobeNewswire
Jan-08-19 08:30AM	Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist GlobeNewswire
Dec-28-18 08:52AM	Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher Zacks +9.73%
Nov-23-18 09:03AM	Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-13-18 07:30AM	Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-12-18 08:30AM	Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference GlobeNewswire -5.06%
Nov-10-18 05:00PM	Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting GlobeNewswire
Nov-05-18 06:31PM	Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018 GlobeNewswire
Nov-02-18 05:12AM	Corvus: 3Q Earnings Snapshot Associated Press
Nov-01-18 04:10PM	Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +8.04%

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MILLER RICHARD A MD	President and CEO	May 04	Buy	2.80	35,714	99,999	35,714	May 05 05:01 PM
MILLER RICHARD A MD	President and CEO	Feb 17	Buy	3.50	100,000	350,000	1,278,515	Feb 17 04:44 PM
ORBIMED ADVISORS LLC	Director	Feb 17	Buy	3.50	1,285,714	4,499,999	8,053,298	Feb 19 04:52 PM
Thompson Peter A.	Director	Feb 17	Buy	3.50	1,285,714	4,499,999	8,053,298	Feb 19 04:47 PM
Novo Holdings A/S	10% Owner	Jul 08	Sale	5.37	741,440	3,985,166	1,389,498	Jul 09 04:35 PM
Novo Holdings A/S	10% Owner	Jul 07	Sale	5.25	796,622	4,183,381	2,130,938	Jul 09 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience